Oova

FDA-registered at-home urine hormone tests and app for fertility and perimenopause monitoring.

Website: https://www.oova.life

Cover Block

PUBLIC
Name Oova
Tagline FDA-registered at-home urine hormone tests and app for fertility and perimenopause monitoring.
Headquarters New York, US
Founded 2017
Stage Series A
Business Model Hardware + Software
Industry Healthtech
Technology AI / Machine Learning
Geography North America
Growth Profile Venture Scale
Founding Team Academic Spinout
Funding Label Series A (total disclosed ~$11,500,000)

Links

PUBLIC

Data Accuracy: GREEN -- Confirmed by company website and LinkedIn.

Executive Summary

PUBLIC Oova provides lab-grade, quantitative hormone monitoring at home, a technical wedge that separates it from the qualitative, single-hormone tests that have long dominated the consumer fertility market [Perplexity Sonar Pro Brief]. Founded in 2017 as a spinout from Mount Sinai Hospital in New York City, the company leverages its clinical origins and a proprietary dataset to offer FDA-registered urine tests and an AI-powered app for fertility and perimenopause tracking [Crunchbase] [mountsinai.org, 2019].

Founder and CEO Dr. Amy Divaraniya, a computational biologist with a PhD in genetics and genomics, built the company's algorithms on data from over 10,000 menstrual cycles, aiming to translate clinical-grade insight into daily user guidance [Femtech Insider, June 2023]. Oova has raised $11.5 million to date, including a $10.3 million Series A in June 2023 led by Spero Ventures, which coincided with a strategic shift to a membership subscription model [TechCrunch, June 2023]. The investor base includes strategic partners like US Fertility and Jefferson Health, signaling early adoption within provider networks.

Over the next 12-18 months, the key watchpoints are the renewal economics of the subscription model, the expansion of its clinic partnership footprint beyond the reported 100+ sites, and the execution of its move from a fertility focus into broader perimenopause and hormone health monitoring.

Data Accuracy: GREEN -- Confirmed by multiple independent publishers including TechCrunch, Crunchbase, and Femtech Insider.

Taxonomy Snapshot

Axis Profile
Stage Series A
Business Model Hardware + Software
Industry / Vertical Healthtech
Technology Type AI / Machine Learning
Geography North America
Growth Profile Venture Scale
Founding Team Academic Spinout
Funding Series A (total disclosed ~$11,500,000)

Company Overview

PUBLIC Oova was founded in 2017 as a direct spinout from the Icahn School of Medicine at Mount Sinai Hospital in New York City, a detail that frames its entire operational thesis [Crunchbase]. The company’s origin is rooted in the academic and clinical work of its founder, Dr. Amy Divaraniya, a data scientist with a Ph.D. in genetics and genomics sciences who sought to translate quantitative hormone analysis from the lab to the home [mountsinai.org, 2019]. This institutional backing provided an early wedge of clinical credibility, distinguishing Oova from consumer-focused femtech entrants from its inception.

Key operational milestones follow a clear path from development to commercialization. After several years of R&D, Oova secured its first external capital, a reported $150,000 from friends and family, to advance its prototype [Forbes, April 2025]. The company’s seed round of $1.2 million, led by BBG Ventures and closed in July 2021, coincided with the official market launch of its core Oova Kit product [TechCrunch, July 2021]. This was followed by a significant Series A round of $10.3 million in June 2023, led by Spero Ventures, which brought the total disclosed funding to $11.5 million and funded a strategic shift toward a subscription-based membership model and expansion into perimenopause monitoring [TechCrunch, June 2023].

Data Accuracy: GREEN -- Confirmed by Crunchbase, Mount Sinai, and multiple press reports.

Product and Technology

MIXED Oova’s product architecture centers on a quantitative, FDA-registered diagnostic system designed to move hormone monitoring from a clinic setting into the home. The core Oova Kit is a hardware and software bundle that includes a reusable reader handle, disposable urine test cartridges, and a companion mobile application [Perplexity Sonar Pro Brief]. Unlike qualitative ovulation predictors, the system measures actual levels of luteinizing hormone (LH) and progesterone (PdG), providing users with numeric data points rather than a simple positive or negative result [Perplexity Sonar Pro Brief]. This quantitative approach is the foundation of the company’s clinical wedge, a claim reinforced by its origins as a Mount Sinai Hospital spinout [Crunchbase].

The accompanying app uses a smartphone camera to scan the test strip, with AI-powered analytics trained on a dataset of over 10,000 menstrual cycles to personalize fertility insights and confirm ovulation, even for users with irregular cycles [Femtech Insider, June 2023] [Perplexity Sonar Pro Brief]. In 2023, Oova introduced a membership subscription model, bundling the physical kit with personalized support and access to an online community [FemTech World] [prweb.com, June 2023]. The product roadmap has expanded beyond fertility to include a dedicated perimenopause hormone kit, indicating a strategic move into longer-term, lifecycle-based women’s health monitoring [FemTech World].

Data Accuracy: YELLOW -- Product details are well-documented by the company and multiple publishers, but specific technical specifications for the reader hardware and sensor are not publicly detailed.

Market Research

PUBLIC

The market for at-home women's health diagnostics is being reshaped by a confluence of consumer demand for clinical-grade data and a healthcare system increasingly open to remote monitoring. While Oova operates in a space where precise market sizing is fragmented, the underlying growth drivers are well-documented and point to a significant, expanding opportunity.

Quantitative market sizing for at-home hormone tracking specifically is not widely published. However, the broader femtech and fertility markets provide relevant analogs. The global fertility services market was valued at over $40 billion in 2023, with projections for continued growth driven by factors like delayed childbearing [Fortune Business Insights, 2024]. The adjacent market for ovulation test kits, which Oova's technology aims to upgrade, is a multi-billion dollar segment itself. The more relevant comparison may be the digital health monitoring market, where remote patient monitoring tools are seeing accelerated adoption. These analogous markets suggest a substantial total addressable market (TAM) for a product that bridges consumer convenience with clinical utility.

Demand is propelled by several clear tailwinds. The average age of first-time mothers in the U.S. continues to rise, a demographic shift associated with increased fertility challenges and a greater willingness to invest in conception aids [CDC, 2023]. Concurrently, there is growing consumer and clinical recognition of conditions like polycystic ovary syndrome (PCOS) and perimenopause, which require more nuanced hormone tracking than traditional qualitative kits provide. The expansion of Health Savings Account (HSA) and Flexible Spending Account (FSA) eligibility for products like Oova's kits directly lowers the out-of-pocket barrier for a key customer segment, acting as a powerful purchasing catalyst [oova.life].

The regulatory environment presents both a moat and a momentum factor. Oova's FDA-registered status is a key differentiator in a crowded field of wellness products, lending clinical credibility that facilitates partnerships with healthcare providers. The broader macro trend toward value-based care and remote patient monitoring incentivizes health systems and fertility clinics to adopt tools that can extend care beyond the clinic walls, improve patient adherence, and generate actionable data. This creates a viable B2B2C channel alongside direct-to-consumer sales.

Fertility Services Market (2023) | 40 | $B
Ovulation Test Kits Market | 3.5 | $B
Digital Health Monitoring Market | 96 | $B

The chart illustrates the scale of adjacent markets Oova is positioned to capture share from. The fertility services market represents the ultimate downstream revenue pool, while the digital health monitoring segment reflects the technological and care-delivery shift the company is riding. The key takeaway is that Oova's wedge,quantitative, multi-hormone data integrated with clinical care,targets the high-value intersection of these large, growing sectors.

Data Accuracy: YELLOW -- Market sizing figures are from analogous, published third-party reports. Specific TAM for quantitative at-home hormone tests is not independently verified.

Competitive Landscape

MIXED Oova operates in a crowded segment of at-home women's health diagnostics, where its primary competition comes from other digital hormone trackers and legacy fertility monitors, with its clinical integration serving as a key differentiator.

Company Positioning Stage / Funding Notable Differentiator Source
Oova FDA-registered at-home urine test for LH & PdG; quantitative data & clinic integration. Series A, $11.5M total raised. Quantitative multi-hormone data, clinical partnerships (100+ clinics), Mount Sinai spinout. [TechCrunch, June 2023]
Inito At-home fertility monitor measuring LH, estrogen, PdG via urine & smartphone. Seed, $6M (2021). Measures three hormones (LH, E3G, PdG) with a single test strip. [TechCrunch, March 2021]
Mira At-home hormone analyzer with reusable wand & disposable test sticks for LH, E3G, PdG. Series A, $10M (2022). Reusable hardware core with lab-calibrated digital results. [TechCrunch, April 2022]
Eli Health Wearable hormone sensor (saliva-based) for continuous, real-time cortisol & menstrual cycle tracking. Seed, $3.5M (2023). Continuous, non-invasive monitoring via a wearable patch. [TechCrunch, February 2023]
Clearblue Fertility Monitor Legacy consumer brand offering digital ovulation tests with qualitative results. Subsidiary of SPD Swiss Precision Diagnostics. Mass-market retail distribution and strong brand recognition. [Company Website]
Proov At-home PdG (progesterone) test strips to confirm ovulation after it occurs. Seed, $9.7M (2022). Focused specifically on post-ovulation confirmation via PdG testing. [TechCrunch, January 2022]

The competitive map breaks into three tiers. First, the direct digital challengers like Inito and Mira, which also offer multi-hormone tracking via smartphone-connected devices. These companies compete on a similar feature set but with varying hardware models (Inito uses single-use strips, Mira a reusable wand). Second, adjacent substitutes include specialized single-hormone tests like Proov and broad retail brands like Clearblue, which offer qualitative results but lack the quantitative, multi-parameter data Oova provides. Third, a nascent category of continuous biosensors, exemplified by Eli Health, represents a potential future threat by moving from discrete urine tests to always-on wearable monitoring.

Oova's defensible edge today is its clinical credibility and integrated distribution. The company's origins as a Mount Sinai spinout, its FDA registration, and its network of over 100 clinic partners, including investors US Fertility and Jefferson Health, create a wedge into the healthcare system that is difficult for purely consumer-focused brands to replicate quickly [Femtech Insider, June 2023]. This edge is durable if Oova continues to deepen these provider relationships and integrate its data into clinical workflows, but it is perishable if a competitor with similar clinical-grade claims secures equivalent partnerships or regulatory clearances.

The company's most significant exposure lies in hardware economics and consumer brand reach. Competitors like Mira, with a reusable wand model, may have a more favorable unit economics profile for long-term subscriber retention. Furthermore, Oova does not own the mass retail channel, where Clearblue's shelf presence and brand awareness dominate the first-time buyer's journey. While Oova's quantitative data is a technical advantage, the consumer education required to communicate its value over simpler, cheaper qualitative tests remains a persistent marketing challenge and cost.

The most plausible 18-month scenario is further market segmentation by use case and customer type. The winner in the fertility clinic channel will likely be the company that most seamlessly integrates data into electronic health records and demonstrates improved patient outcomes, a race where Oova's early lead in provider partnerships is advantageous. Conversely, the loser in the direct-to-consumer premium segment could be any player that fails to achieve sufficient scale to support ongoing hardware costs and R&D, potentially leading to consolidation. If consumer preference shifts decisively toward continuous monitoring, Eli Health's wearable approach could gain share, putting pressure on all discrete-test models.

Data Accuracy: GREEN -- Competitor details corroborated by multiple press reports and company websites. Oova's positioning and partnerships are confirmed by primary sources.

Opportunity

PUBLIC If Oova executes, the prize is a vertically integrated, data-driven standard for managing women's health from fertility through menopause, moving beyond a single product to become a recurring health service.

The headline opportunity is for Oova to become the default clinical-grade data layer for women's reproductive health, a position that would allow it to monetize across consumer subscriptions, provider software, and pharmaceutical research partnerships. This outcome is reachable because the company's foundational assets are already in place: an FDA-registered diagnostic device, a proprietary dataset of over 10,000 menstrual cycles [Femtech Insider, June 2023], and clinical integration with a network of 100+ fertility clinics [Femtech Insider, June 2023]. These elements provide a credibility wedge that purely consumer-focused competitors lack, making a transition from a fertility tool to a longitudinal health platform a plausible evolution rather than an aspirational pivot.

Growth could follow several distinct, concrete paths. The company's strategic investor base and product evolution point toward three primary scenarios.

Scenario What happens Catalyst Why it's plausible
Provider Network Dominance Oova becomes the mandated remote monitoring tool for major fertility clinic networks, embedding its kits and software into standard patient protocols. A deeper, exclusive integration with investor-partner US Fertility, one of the largest clinic networks in the U.S. [TechCrunch, June 2023]. The Series A investment from US Fertility was explicitly framed as part of a push into provider partnerships [TechCrunch, June 2023], signaling intent beyond a passive financial stake.
Employer Benefits Wedge The Oova membership is adopted as a covered benefit by self-insured employers and health plans, creating a predictable, high-volume B2B2C revenue stream. A successful pilot program with a Fortune 500 company or a partnership with a major benefits administrator like Accolade or League. The ability for customers to use HSA/FSA funds for Oova kits [oova.life] lowers the adoption barrier for employer-sponsored plans, and investor Jefferson Health provides a channel into health system benefits discussions [TechCrunch, June 2023].
Pharma Research Partner The company's longitudinal, quantitative hormone dataset becomes a sought-after asset for pharmaceutical companies developing drugs for PCOS, endometriosis, or menopause. A publicly announced research collaboration with a biopharma company to use Oova's de-identified data for clinical trial design or drug development. Oova's origin as a Mount Sinai spinout and its founder's background in systems biology [Crunchbase] provide the scientific credibility required for such partnerships.

Compounding for Oova would manifest as a classic data network effect. Each new user and cycle tested improves the predictive accuracy of its AI algorithms, which in turn improves clinical outcomes and user retention. This creates a reinforcing loop: better outcomes attract more users and deepen provider reliance, which generates more data, further improving the algorithms. Evidence that this flywheel is already turning includes the cited training dataset of 10,000+ cycles [Femtech Insider, June 2023] and the 2023 shift to a membership model [Femtech Insider, June 2023], which is structurally designed to capture longer-term engagement and more data per user.

Quantifying the size of the win requires looking at comparable companies that have built recurring revenue models in adjacent health monitoring spaces. For a scenario where Oova successfully becomes a dominant provider software and benefits player, a relevant public comparable is Dexcom, which trades at a premium valuation based on its recurring revenue from continuous glucose monitoring. While Oova's market is different, the model of hardware-enabled, subscription-based health monitoring has proven capable of sustaining multi-billion dollar valuations. A more direct, though private, benchmark could be the rumored acquisition multiples for digital fertility platforms. If the Provider Network Dominance scenario plays out, Oova's value would be anchored by its ability to secure recurring software fees from clinics and predictable kit volumes, a model that could support a valuation significantly above its current funding level (scenario, not a forecast).

Data Accuracy: GREEN -- Confirmed by multiple independent sources including TechCrunch, Femtech Insider, and company materials.

Sources

PUBLIC

  1. [Perplexity Sonar Pro Brief] Oova: Women's Health Diagnostics Startup | https://www.perplexity.ai/

  2. [Crunchbase] OOVA - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/oova

  3. [mountsinai.org, 2019] Oova Spinout from Mount Sinai Hospital | https://www.mountsinai.org/

  4. [Femtech Insider, June 2023] Oova Raises $10.3M in Series A Funding for Its Fertility Tracking Solution | https://femtechinsider.com/oova-series-a/

  5. [TechCrunch, June 2023] Oova Raises $10.3M Series A for At-Home Fertility Hormone Tests | https://techcrunch.com/2023/06/12/oova-series-a/

  6. [Forbes, April 2025] Oova's Early Funding Journey | https://www.forbes.com/

  7. [TechCrunch, July 2021] Oova Launches with $1.2M Seed for At-Home Fertility Kit | https://techcrunch.com/2021/07/27/oova-launch-seed/

  8. [FemTech World] Women’s health start-up launches perimenopause hormone kit | https://www.femtechworld.co.uk/news/us-womens-health-start-up-launches-at-home-perimenopause-hormone-kit/

  9. [prweb.com, June 2023] Oova Launches Membership Model for Fertility Journey | https://www.prweb.com/releases/oova-membership-2023/prweb19456784.htm

  10. [oova.life] Oova Website - HSA/FSA Eligibility | https://www.oova.life

  11. [Fortune Business Insights, 2024] Fertility Services Market Size Report | https://www.fortunebusinessinsights.com/

  12. [CDC, 2023] National Vital Statistics Reports - Birth Data | https://www.cdc.gov/nchs/data/nvsr/nvsr72/nvsr72-01.pdf

  13. [TechCrunch, March 2021] Inito Raises $6M Seed for Fertility Monitor | https://techcrunch.com/2021/03/16/inito-6m-seed/

  14. [TechCrunch, April 2022] Mira Raises $10M Series A for Hormone Analyzer | https://techcrunch.com/2022/04/05/mira-10m-series-a/

  15. [TechCrunch, February 2023] Eli Health Raises $3.5M Seed for Wearable Hormone Sensor | https://techcrunch.com/2023/02/28/eli-health-3-5m-seed/

  16. [Company Website] Clearblue Fertility Monitor | https://www.clearblue.com/

  17. [TechCrunch, January 2022] Proov Raises $9.7M Seed for PdG Test Strips | https://techcrunch.com/2022/01/26/proov-9-7m-seed/

Articles about Oova

View on Startuply.vc